A revolution in drug approval practices is requiredBMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e8002 (Published 26 November 2012) Cite this as: BMJ 2012;345:e8002
- Alastair Mander, geriatrician1
- 1Private Practice, Suite 3, Geelong Private Medical Centre, Geelong, VIC 3220 Australia
This is a topic that requires a revolution in practices.1 Currently, when manufacturers submit data to the regulator, they have to provide data on all completed trials. The regulator may ask for further data but once satisfied gives approval or denial for marketing. The data then provided to the public and …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial